Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Change in Account Payables: 2020-2024

Historic Change in Account Payables for Immuneering (IMRX) over the last 5 years, with Dec 2024 value amounting to -$112,143.

  • Immuneering's Change in Account Payables fell 66.73% to $56,741 in Q4 2024 from the same period last year, while for Dec 2024 it was -$112,143, marking a year-over-year increase of 89.87%. This contributed to the annual value of -$112,143 for FY2024, which is 89.87% up from last year.
  • As of FY2024, Immuneering's Change in Account Payables stood at -$112,143, which was up 89.87% from -$1.1 million recorded in FY2023.
  • Immuneering's Change in Account Payables' 5-year high stood at $1.8 million during FY2022, with a 5-year trough of -$1.1 million in FY2023.
  • Its 3-year average for Change in Account Payables is $180,393, with a median of -$112,143 in 2024.
  • As far as peak fluctuations go, Immuneering's Change in Account Payables skyrocketed by 1,449.88% in 2022, and later crashed by 162.88% in 2023.
  • Immuneering's Change in Account Payables (Yearly) stood at $1.2 million in 2020, then slumped by 111.00% to -$130,398 in 2021, then spiked by 1,449.88% to $1.8 million in 2022, then crashed by 162.88% to -$1.1 million in 2023, then skyrocketed by 89.87% to -$112,143 in 2024.